As a following step, we sought to explore the concept of molecular hybridization by covalently linking SRPK1 inhibitors with antimetabolites, inspired by previous research showing that targeting of SRPK1 results in enhanced sensitivity to platinum-based drugs in some types of cancer.2,4 Our aim was to evaluate whether these hybrids could exhibit enhanced potency, improved physicochemical properties, or new mechanisms of action compared to the parent pharmacophores. The gene discussed is SRPK1; the disease is cancer.